Fiduciary Group Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Fiduciary Group reduced its stake in AbbVie Inc by 1.28% during the most recent quarter end. The investment management company now holds a total of 69,178 shares of AbbVie Inc which is valued at $4,648,070 after selling 894 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.AbbVie Inc makes up approximately 1.25% of Fiduciary Group’s portfolio.

Other Hedge Funds, Including , Homrich Berg boosted its stake in ABBV in the latest quarter, The investment management firm added 186 additional shares and now holds a total of 13,450 shares of AbbVie Inc which is valued at $903,706. AbbVie Inc makes up approx 0.08% of Homrich Berg’s portfolio. Edge Asset Management Inc sold out all of its stake in ABBV during the most recent quarter. The investment firm sold 118,344 shares of ABBV which is valued $7,850,941.Barbara Oil boosted its stake in ABBV in the latest quarter, The investment management firm added 2,500 additional shares and now holds a total of 20,000 shares of AbbVie Inc which is valued at $1,339,000. AbbVie Inc makes up approx 1.05% of Barbara Oil’s portfolio.Rehmann Capital Advisory Group boosted its stake in ABBV in the latest quarter, The investment management firm added 4,358 additional shares and now holds a total of 22,047 shares of AbbVie Inc which is valued at $1,430,850. AbbVie Inc makes up approx 0.26% of Rehmann Capital Advisory Group’s portfolio.

AbbVie Inc opened for trading at $66.57 and hit $67.18 on the upside on Friday, eventually ending the session at $67.1, with a gain of 0.49% or 0.33 points. The heightened volatility saw the trading volume jump to 67,09,360 shares. Company has a market cap of $109,275 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.